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Lamin A is a component of the nuclear lamina mutated in a
group of human inherited disorders known as laminopathies.
Among laminopathies, progeroid syndromes and lipodystro-
phies  feature accumulation of prelamin A, the precursor pro-
tein which, in normal cells, undergoes a multi-step processing
to yield mature lamin A. It is of utmost importance to charac-
terize the prelamin A form accumulated in each laminopathy,
since existing evidence shows that drugs acting on protein
processing can improve some pathological aspects.We report
that two antibodies raised against differently modified
prelamin A peptides show a clear specificity to full-length
prelamin  A or carboxymethylated farnesylated prelamin A,
respectively. Using these antibodies, we demonstrated that
inhibition of the prelamin A endoprotease ZMPSTE24 mostly
elicits accumulation of full-length prelamin A in its farnesylat-
ed form, while loss of the prelamin A cleavage site causes
accumulation of carboxymethylated prelamin A in progeria
cells. These results suggest a major role of ZMPSTE24 in the
first prelamin A cleavage step.
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L
amin A is a major component of the nuclear
lamina which plays different and not yet
completely understood roles in nuclear enve-
lope and chromatin dynamics (Broers et al., 2006;
Vlcek and Foisner, 2007). It is encoded by the
LMNA gene on chromosome 1q21, which is tran-
scribed as different splicing products including
lamin A, lamin C, lamin A ∆ 10 and lamin C2
(Arora et al., 2004).
Lamin A is translated as a precursor protein har-
bouring a C-terminus CaaX sequence, which is typi-
cal of farnesylated proteins (Corrigan et al.,2005).
In prelamin A, the CaaX sequence is made up of
cysteine, serine, isoleucine and methionine (CSIM)
(Corrigan et al., 2005). Methionine directs farnesy-
lation at the cysteine residue by the enzyme protein
farnesyltransferase. Following cysteine farnesyla-
tion, the SIM sequence is removed by the endopro-
tease ZMPSTE24. This proteolytic reaction is
thought to be also carried out by the endoprotease
RCE1, which could replace ZMPSTE24 (Rusinol
and Sinensky, 2006). The cysteine residue is then
methylated by the methyltransferase Icmt and a
final proteolytic cleavage, performed by ZMP-
STE24,removes a further 15 C-terminal residues to
produce mature lamin A (Rusinol and Sinensky,
2006). Thus, at least four prelamin A species are
transiently formed during prelamin A maturation,
including unprocessed prelamin A, which is not far-
nesylated (preLA-CSIM), farnesylated full-length
prelamin A (preLA- farnesyl-CSIM), farnesylated
prelamin A lacking the SIM sequence (preLA-far-
nesyl-C), and carboxymethylated-farnesylated
prelamin A (preLA-farnesyl-C-CH3).
The knowledge of which prelamin A form is actu-
ally more represented  in normal and pathological
cells is of utmost importance. In fact, all prelamin
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mature protein (Rusinol and Sinensky, 2006), so
that the complex mechanism leading to prelamin A
maturation must play per se some functional role,
which has not been completely unravelled. Data so
far reported show that the lamin A precursor
affects to some extent nuclear envelope targeting of
the mature protein (Hennekes and Nigg, 1994),
transcription factor translocation (Caron et al.,
2003; Capanni et al., 2005) and chromatin organ-
ization (Lattanzi et al., 2007; Mattioli  et al.,
2008). Moreover, an accumulation of mutated or
wild-type prelamin A has been shown in several
laminopathies, linked to LMNA or  ZMPSTE24
gene mutations,including Hutchinson-Gilford prog-
eria syndrome (HGPS), Restrictive Dermopathy
(RD), Mandibuloacral dysplasia type A (MADA)
and B (MADB), atypical Werner syndrome (WS),
familial partial lipodystrophies and metabolic
laminopathies (De Sandre-Giovannoli et al., 2003;
Eriksson  et al., 2003; Navarro  et al., 2004;
Capanni et al., 2005; Filesi et al., 2005;Young et
al., 2005; Caron  et al., 2007; Maraldi and
Lattanzi, 2007; Maraldi  et al., 2006, 2007). In
addition, we and others have shown that some HIV
protease inhibitors used in anti-retroviral therapy
inhibit ZMPSTE24, leading to a secondary
laminopathy (Caron et al., 2003; Caron  et al.,
2007;Coffinier et al.,2007;Coffinier et al.,2008).
A number of published data show that prelamin A
accumulation is toxic to cells and that protein toxi-
city could be not only dependent on protein amount,
but also on the post-translational modification har-
boured by the precursor itself (Caron et al., 2007;
Lattanzi  et al., 2007b; Yang  et al., 2008).
Therefore, the availability of antibodies directed to
different prelamin A forms could allow a relevant
advance in the study of prelamin A effects.
Here we report construction and validation of two
different antibodies raised in rabbit against
prelamin A C-terminus peptides. The first one,
called 1188-1, has been developed against the last
18 aminoacids in the prelamin A C-terminus,
including the CSIM motif. The second antibody,
called 1188-2, has been obtained using a farnesy-
lated prelamin A C-terminus peptide lacking the
last three aminoacids in the CSIM sequence. Here
we demonstrate that the 1188-1 antibody is able to
bind non-farnesylated prelamin A  and, with lower
affinity, farnesylated full-length prelamin A. The
second antibody,on the contrary,does not recognize
preLA-CSIM and selectively binds carboxylated or
carboxymethylated prelamin A harbouring the far-
nesyl residue. These antibodies could represent a
useful tool to investigate the biological significance
of prelamin A processing and to discriminate which
prelamin A forms are accumulated in
laminopathies (Maraldi and Lattanzi, 2007).
Moreover, they can be used to monitor the effects
of drugs acting on prelamin A processing, which
are potential therapeutic tools in laminopathies
featuring prelamin A accumulation (Caron et al.,
2007) and in cancer therapy (Adjei et al., 2000;
Ramirez et al., 2007). Using these antibodies in
experimental models of prelamin A accumulation
and in HGPS cells, we could determine that the
first cleavage step of prelamin A processing is
mostly catalysed by the ZMPSTE24 endoprotease,
whose inhibition causes accumulation of full-
length farnesylated prelamin A.
Materials and Methods
Antibodies preparation  
Peptides LLGNSSPRTQSPQNCSIM (peptide
1188-1) and LLGNSSPRTQSPQNC-Farnesyl
(peptide 1188-2), which represent aminoacidic
sequences involved in the lamin A maturation path-
way, were obtained by chemical synthesis (BIO-
SYNTHESIS, Lewisville, USA) (for peptide analy-
sis see Figures 1 and 2). Peptides were converted
into haptens by combination with keyhole limpet
hemocyanin (KLH) used as carrier, in order to
increase their immunogenic properties. Synthetic
peptides KLH-conjugated emulsified with
Incomplete Freund’s adjuvant (IFA) were injected
into New Zealand White rabbits for antibody pro-
duction. Plasma was collected by centrifugation
(2,800 rpm for 10 min). Immunoglobulin fractions
were purified from rabbit antiserum by Protein A
affinity chromatography (Sigma). Immunoglo-
bulins were eluted with sodium citrate 0.1 M pH
3.0 and immediately neutralized with 1 M TRIS
(100 µl/mL).
Antibody characterization
Antibody specificity was tested by ELISA.
LLGNSSPRTQSPQNCSIM and LLGNSSPRTQS
PQNC-Farnesyl synthetic peptides (5 µg/mL) dis-
solved in 50 mM NaHCO3 pH 9.6 or prelamin A
and lamin A recombinant proteins (1 µg/mL) dis-
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Figure 1. Prelamin A process-
ing and prelamin A specific
sequences. (A) The scheme
shows the subsequent
prelamin A processing steps
(1 to 4) and the prelamin A
processing intermediates. The
names used in this study for
each prelamin A form are
reported on the right. The pro-
tein residues targeted by anti-
prelamin A antibodies 1188-1
(boxed area in preLA-CSIM)
and 1188-2 (boxed area in
preLA-farnesyl-C) are high-
lighted. Reported in (B) and
(C) are the sequences of the
prelamin A-specific peptides
used to produce antibody
1188-1 and 1188-2, respec-
tively. The mass spectrum of
each peptide is shown in (D)
(peptide 1188-1) and (E) (pep-
tide 1188-2). Aminoacid sym-
bols in (A), (B) and (C) are in
red characters. 
Figure 2. Antibodies 1188-1
and 1188-2  react with
prelamin A, but not mature
lamin A. (A) ELISA was per-
formed on 1188-1 peptide to
evaluate the affinity of anti-
body 1188-1. The binding
activity of 1188-2 antibody is
shown as a control. (B) ELISA
was performed on 1188-2 pep-
tide to evaluate the affinity of
antibody 1188-2. The binding
activity of 1188-1 antibody is
shown as a control.  (C)
Binding affinity of antibodies
1188-1 and 1188-2 for recom-
binant full-length prelamin A
or mature lamin A (D) was
evaluated by ELISA. Antibody
1188-1 bound full-length
prelamin A but not mature
lamin A. Antibody 1188-2 did
not bind neither full-length
prelamin A, nor mature lamin
A. solved in 50 mM NaHCO3 pH 9.6 were incubated at
4°C for 18 hours in 96 well plates. A detailed
description of recombinant human prelamin A and
lamin A purification will be reported elsewhere.
Briefly,recombinant prelamin A (rPrelamin A) had
been translated as a 74 kDa full-length precursor,
while lamin A had been translated as a 70 kDa
mature protein using a mutated LMNA construct.
After discarding peptide and protein excess, the
plates were blocked with PBS containing 0.05%
(v/v) Tween 20 and 1% (w/v) BSA for 1 hour at
37°C. After washing, 100 µL of immune serum
diluted in PBS containing 1% (w/v) BSA were
added to each well and incubated at 37°C for 1
hour. Plates were washed and an HRP-conjugated
anti-rabbit antibody (Bio-Rad Laboratories) was
added and incubated for 1 hour at 37°C. The
immune reaction was developed using 2,2’-azino-
bis 3-ethylbenzthiazoline-6-sulfonic acid as sub-
strate dissolved in a Colour buffer (50 mM of sodi-
um citrate pH 3.0 with 1 µl/mL of H2O2). The
absorbance at 405 nm was measured using a
microplate reader (Bio-Rad Laboratories).
Cell cultures 
Skin fibroblast cultures were obtained from skin
biopsies of healthy patients (mean age 24) under-
going orthopaedic surgery, following a written con-
sent.HGPS fibroblast cell cultures were established
from a skin biopsy of a 5 year old patient undergo-
ing genetic analysis. The protocol had been
approved by the local ethical committees. The
c.1824C>T/p.G608G variation within the LMNA
gene was identified by direct sequencing as previ-
ously described (De Sandre-Giovannoli et al.,
2003). Cell cultures were established and cultured
in Dulbecco’s modified Eagle’s medium supple-
mented with 20% fetal calf serum (FCS) and
antibiotics.The experiments were performed at pas-
sages 3 to 10.
Drug treatments
Ten  µM FTI-277 (Calbiochem, Merck
Biosciences) or 20 µM mevinolin (Sigma-Aldrich)
were applied to control fibroblasts  for 18 hours.
These drugs impair prelamin A farnesylation
through different mechanisms. FTI-277 inhibits
farnesyltransferase activity through a pep-
tidomimetic mechanism (Mattioli et al., 2008),
mevinolin is a statin causing inhibition of hydrox-
ymethyl-glutaryl-synthase implicated in the farne-
syl pathway (Verstraeten et al., 2006). Both com-
pounds elicit accumulation of non-farnesylated
prelamin A, as reported in several studies (Glynn
and Glover, 2005;Young et al., 2006; Caron et al.,
2007;Mattioli et al.,2008).1-N-acetyl-S-farnesyl-
L-cysteine methylester (AFCMe, ALEXIS
Biochemicals) was applied at 10 µM concentration
in culture medium for 18 hours. AFCMe is a  non-
peptidomimetic compound known to impair binding
of the ZMPSTE24 endoprotease to prelamin A,
thus affecting proteolytic steps and causing accu-
mulation of  farnesylated prelamin A. Protease
inhibitors used in HIV anti-retroviral therapy were
employed in our study to induce accumulation  of
farnesylated prelamin A. These drugs include the
known prelamin A processing inhibitors nelfinavir,
indinavir,lopinavir and ritonavir and two molecules
recently shown to have modest or no impact on
prelamin A maturation (atazanavir and ampre-
navir) (Caron et al., 2007; Coffinier et al., 2008).
Human control cultured fibroblasts were continu-
ously incubated for 7 weeks with HIV protease
inhibitors at concentration close to their Cmax
(indinavir 10 µM, nelfinavir 5 µM, atazanavir 
5 µM, amprenavir 10 µM, and the combinations
lopinavir 10 µM plus ritonavir 2 µM or atazanavir
5 µM plus ritonavir 2 µM, frequently used for the
treatment of patients). Indinavir was provided by
Merck Sharp & Dohme Laboratories (Clermont-
Ferrand, France), nelfinavir by Agouron
Pharmaceuticals (San Diego, CA, USA), ampre-
navir by Vertex Pharmaceuticals (Cambridge, MA,
USA) and lopinavir and ritonavir by Abbott
(Rungis, France). Atazanavir was provided by Dr. S
Azoulay (CNRS UMR 6001, University Nice-
Sophia Antipolis, France).
Immunofluorescence microscopy 
Human fibroblasts grown on glass coverslips were
fixed in methanol at -20°C for 7 minutes,washed in
PBS and subjected to immunofluorescence label-
ing. Samples were incubated with primary antibod-
ies overnight at 4°C in PBS containing 4% BSA to
saturate non-specific binding sites, and with sec-
ondary antibodies for 1 hour at room temperature.
Anti-prelamin A 1188-1 was applied at 1:100 dilu-
tion and anti-prelamin A 1188-2 was applied at
1:10 dilution. HGPS fibroblasts were also stained
with 1188-2 antibody at higher further dilutions up
to 1:150. Nuclei were counterstained with DAPI.
Slides were mounted with an anti-fade reagent in
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cence microscope equipped with a digital camera.
Western blot analysis
Antibody specificity to recombinant prelamin A
(unprocessed protein precursor) or mature lamin A
was tested by Western blot analysis. Recombinant
proteins previously separated on 10% SDS-PAGE
and transferred onto nitrocellulose membranes
were reacted with serial dilutions of purified anti-
bodies 1188-1 and 1188-2.
To evaluate antibody labeling in human fibrob-
lasts,cells were lysed in Ripa buffer containing 1%
Nonidet P-40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EGTA, 1mM PMFS, 1 µM
aprotinin, leupeptin, pepstatin. Cell lysates were
diluted in Laemmli buffer, subjected to SDS-PAGE
(7.5%) and transferred to nitrocellulose mem-
brane. Membranes were saturated with 4% BSA
and incubated with primary antibodies for 1 hour at
room temperature. Both anti-prelamin A 1188-1
and anti-prelamin A 1188-2 were applied at 1:100
dilution. Anti-lamin A/C antibody (Santa Cruz
Biotechnology, SC-7292,) was applied at 1:100
dilution; anti-βactin-antibody was used at 1:1000
dilution as a loading control. Secondary antibodies
were applied for 20 minutes at room temperature.
Immunoblotted bands were revealed by the
Amersham ECL detection system (GE Healthcare).
Results and Discussion
The complex mechanism of prelamin A process-
ing has been summarized in Figure 1A. Among the
prelamin A forms reported in the scheme, the two
antibodies developed in this study were expected to
detect full-length non-farnesylated prelamin A
(preLA-CSIM) and farnesylated prelamin A lack-
ing the C-terminal SIM sequence  (preLA-farnesyl-
C), respectively. Our results clearly show that  anti-
body 1188-1 detects full-length non-farnesylated
prelamin A (preLA-CSIM) and, with lower affinity,
also full length farnesylated prelamin A (preLA-
farnesyl-CSIM).Moreover,antibody 1188-2 specif-
ically recognises farnesylated prelamin A lacking
the C-terminal SIM sequence (preLA-farnesyl-C),
but not the full-length protein. To our knowledge,
antibody 1188-2 is the first antibody that selective-
ly binds preLA-farnesyl-C or preLA-farnesyl-C-
CH3.
Data obtained in human skin fibroblasts demon-
strate that a huge amount of full-length non-farne-
sylated prelamin A (preLA-CSIM) is accumulated
in fibroblasts by inhibition of protein farnesylation,
while a significant amount of full-length farnesylat-
ed prelamin A is accumulated by blockade of ZMP-
STE24 activity. Moreover, we show that car-
boxymethylated farnesylated prelamin A (preLA-
farnesyl-C-CH3), although clearly detectable in
progeria cells as the truncated form called prog-
erin,is recovered in low amounts when ZMPSTE24
activity is inhibited.
Antibody 1188-1 selectively binds full-length
prelamin A in vitro
Antibody 1188-1 was raised against the last 18
aminoacids of the prelamin A sequence.Post-trans-
lational modifications were not introduced in the
peptide used to immunize rabbits, as reported
above (Figure 1B). Antibody characterization was
performed by ELISA on plates coated with the pep-
tide LLGNSSPRTQSPQNCSIM or plates coated
with recombinant full-length prelamin A (preLA-
CSIM). 1188-1 antibody was also tested on plates
coated with LLGNSSPRTQSPQNC-Farnesyl pep-
tide (peptide 1188-2) and recombinant mature
lamin A. The results clearly demonstrate that the
antibody 1188-1 displays high affinity for the pep-
tide LLGNSSPRTQSPQNCSIM (Figure 2A). A
low cross reactivity of 1188-1 antibody on peptide
1188-2 was observed only at very high concentra-
tions (Figure 2B). Moreover, antibody 1188-1
showed high affinity to full-length unprocessed
prelamin A (preLA-CSIM), as determined on
recombinant prelamin A-coating (Figure 2C), but
did not bind recombinant mature lamin A (Figure
2D).The specificity of 1188-1 antibody to prelamin
A was confirmed  by Western blot analysis on
recombinant proteins (not shown).
Antibody 1188-2 selectively binds carboxymethy-
lated farnesylated prelamin A in vitro
Antibody 1188-2 was raised against a farnesylat-
ed peptide made up of the last 15 aminoacids of
prelamin A, lacking the terminal SIM sequence
(preLA-farnesyl-C, Figure 1C). ELISA performed
to check antibody specificity was done on plates
coated with the synthetic peptide
LLGNSSPRTQSPQNC-Farnesyl (peptide 1188-2).
The same  antibody solutions were tested on
LLGNSSPRTQSPQNCSIM peptide (peptide 1188-
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plates. The results demonstrate that antibody
1188-2 reacts with 1188-2 peptide, but not with
1188-1 peptide (Figure 2A, B). Moreover, ELISA
performed on full-length prelamin A (preLA-
CSIM)-coated wells showed no cross-reactivity of
the antibody (Figure 2C, D).The specificity of anti-
body 1188-2 to prelamin A was further investigat-
ed by Western blot analysis. As expected, no
immunoreactive bands were detected on any of the
two proteins (data not shown), showing that anti-
body 1188-2 does not recognize full-length
prelamin A or mature lamin A.
Antibody 1188-1 reacts with non-farnesylated
prelamin A in human fibroblasts
Antibody 1188-1 was used to detect prelamin A
forms in control human fibroblasts either untreated
or treated in vivo with prelamin A processing
inhibitors. Antibody 1188-1 did not stain the
nuclear rim in untreated human fibroblasts (Figure
3A). A faint labelling of intranuclear aggregates
was observed in a minor percentage (<10%) of
cells (not shown). Following FTI-277 or mevinolin
treatment, which cause accumulation of non-farne-
sylated prelamin A (preLA-CSIM) (Verstraeten et
al., 2006; Mattioli et al., 2008), human fibroblasts
were highly positive to 1188-1 antibody staining,
showing a clear nuclear rim labelling (Figure 3A).
Moreover,intranuclear prelamin A aggregates were
sharply labelled (Figure 3A), as expected for non-
farnesylated prelamin A (Lattanzi et al., 2007;
Mattioli et al., 2008).
Antibody 1188-1 detects full-length farnesylated
prelamin A in human fibroblasts
Since we could not rule out the possibility that
antibody 1188-1 might detect farnesylated full-
length prelamin A (preLA-farnesyl-CSIM), we
checked antibody reactivity in cells accumulating
farnesylated prelamin A. In order to induce the
accumulation of farnesylated forms of prelamin A,
we used a set of drugs known to block ZMPSTE24
binding or activity. The non-peptidomimetic com-
pound N-acetyl-S-farnesyl-L-cysteine methylester
(AFCMe) impairs ZMPSTE24 binding to prelamin
A (Corrigan et al., 2005; Mattioli et al., 2008),
while the HIV protease inhibitors are known to
cause prelamin A accumulation, and lopinavir has
been recently shown to inhibit ZMPSTE24 activity
and cause accumulation of farnesylated prelamin A
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Figure 3. Prelamin A staining in control and HGPS skin fibrob-
lasts. Prelamin A staining is shown  in human control fibroblasts
untreated (control) or treated with prelamin A processing
inhibitors and in HGPS fibroblasts. (A) Fibroblasts untreated or
treated with FTI-277 or mevinolin to accumulate non-farnesylat-
ed prelamin A (preLA-CSIM). Antibody 1188-1 labeling is report-
ed in the upper row, antibody 1188-2 labeling is reported in the
lower row. (B) Fibroblasts untreated or treated with AFCMe or
HIV protease inhibitors (combinations of lopinavir plus ritonavir
and atazanavir plus ritonavir, as indicated) to accumulate farne-
sylated prelamin A. HGPS fibroblasts, which also accumulate a
farnesylated prelamin A form, are on the right. Antibody 1188-1
labeling is reported in the upper row, antibody 1188-2 labeling is
reported in the lower row. (C) HGPS fibroblasts treated with mevi-
nolin for 48 hours to show reduced staining using 1188-2 anti-
body with respect to bright staining observed in untreated HGPS
cells shown in (B) and (D). Prelamin A staining was revealed by
FITC-conjugated anti-rabbit IgG (green). Bars, 10 µ µm.(Coffinier et al., 2008). Figure 3B shows that cells
treated with AFCMe or the combination of
lopinavir-ritonavir or atazanavir-ritonavir are posi-
tive to 1188-1 staining,suggesting that even farne-
sylated prelamin A can be recognized by the anti-
body, provided that the SIM sequence has not been
removed. The presence of enlarged nuclei in
AFCMe-treated cells (Figure 3B) is consistent with
accumulation of farnesylated prelamin A (Mattioli
et al.,2008).On the other hand, intranuclear stain-
ing might suggest  that full-length non farnesylated
prelamin A (preLA-CSIM) is also accumulated in
HIV protease inhibitor-treated cells. Noteworthy,
atazanavir and amprenavir did not  induce nuclear
staining with 1188-1 antibody,indicating,in accor-
dance with our previous results (Mattioli et al.,
2008), that they do not inhibit ZMPSTE24 (not
shown).
Antibody 1188-2 reacts with carboxymethylated-
farnesylated prelamin A in human fibroblasts 
To check the specificity of antibody 1188-2 we
again used FTI-277 or mevinolin to induce accu-
mulation of non-farnesylated prelamin A in human
fibroblasts. Moreover, we used AFCMe and HIV
protease inhibitors to induce accumulation of far-
nesylated prelamin A forms, as reported above. In
addition, we reasoned that the only cell model
shown to accumulate a carboxymethylated and far-
nesylated prelamin A form is represented by HGPS
cells (Dechat et al., 2007). In those cells  prelamin
A is accumulated as progerin,a truncated prelamin
A form obtained by alternative splicing,which lacks
the second ZMPSTE24 cleavage site (Eriksson et
al.,2003).Therefore,we checked HGPS fibroblasts
for antibody 1188-2 staining of progerin.
The results reported in Figure 3A show that
human control cells either untreated or accumulat-
ing non-farnesylated prelamin A by FTI-277 or
mevinolin treatment are negative to 1188-2 anti-
body staining at the nuclear periphery,while a faint
intranuclear labelling is detected (Figure 3A).This
result shows that the 1188-2 antibody does not rec-
ognize non-farnesylated prelamin A. On the other
hand, in cells treated with AFCMe low staining by
1188-2 antibody was observed (Figure 3B),as well
as in fibroblasts subjected to HIV protease
inhibitor treatment (Figure 3B). The antibody
labelled the nuclear rim, but also the nucleoplasm.
The latter was an unexpected finding, which was
however supported by experiments performed in
pathological models,using different antibodies (our
unpublished results). Moreover, nucleoplasmic
localization of prelamin A had been previously
reported in a human cell line (Gruber et al.,2005).
Data obtained in HGPS were striking. Since the
antibody was obtained by taking advantage of the
antigenicity properties of the farnesylated prelamin
A C-terminus lacking the SIM sequence,we hypoth-
esized that it had to be able to recognize progerin,
the  truncated prelamin A form accumulated in
HGPS, which had been shown to harbour that
sequence (Dechat et al., 2007). In fact, we show
that the highest labelling efficiency of 1188-2 anti-
body is observed in HGPS fibroblasts, showing a
strong nuclear rim staining in highly dysmorphic
nuclei and a nuclear rim and intranuclear staining
in ovoid nuclei (Figure 3B). It should be noted that
antibody 1188-2 still labelled progerin when
applied at higher dilution (Figure 3B), while it
failed to label AFCMe-treated cells at this dilution
(not shown). These results demonstrate that anti-
body 1188-2 selectively and efficiently labels car-
boxymethylated farnesylated prelamin A.
Western blot analysis of drug-treated fibroblasts
shows high specificity of antibodies
Figure 4 shows the Western blot analysis of
prelamin A in different samples performed using
1188-1 or 1188-2 antibody. In lysates from
untreated control fibroblasts, antibody 1188-1
failed to reveal any protein band (Figure 4).
Lysates from FTI-277 or mevinolin-treated cells,
which are expected to accumulate preLA-CSIM,
were strongly positive for 1188-1 staining (Figure
4). Cellular lysates from AFCMe-treated fibrob-
lasts were also positive for anti-prelamin A 1188-1
staining, but a reduced amount of protein was
detected, despite equal protein loading (Figure 4).
This could be due to a lower affinity of the antibody
for the farnesylated form of the full-length prelamin
A. However, a sharp prelamin A band was detected
with 1188-1 in samples treated with indinavir, nel-
finavir, or the combination of lopinavir-ritonavir or
atazanavir-ritonavir,while no staining was detected
in amprenavir or atazanavir-only treated cells
(Figure 4).These findings suggest that AFCMe and
HIV protease inhibitors could affect prelamin A
processing to different extent. 1188-1 antibody did
not label any protein band in HGPS cellular
lysates, suggesting that a minimal amount of full-
length prelamin A, if any, is accumulated in those
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nolin or FTI-277-treated cells were not labelled
with 1188-2 antibody, showing that the antibody
1188-2 does not cross-react with mature lamin A
or with preLA-CSIM (Figure 4). A faint 74 kDa
prelamin A band was labelled by 1188-2 antibody
in AFCMe-treated fibroblast lysates, and in cells
treated with indinavir,nelfinavir,or combinations of
HIV-protease inhibitors containing ritonavir
(Figure 4). Importantly, a sharply labelled progerin
band (68 kDa) was detected using 1188-2 antibody
in HGPS cell lysates (Figure 4).Since only the last
four aminoacids of the peptide used to produce
1188-2 and the farnesyl residue are present in the
progerin sequence (Eriksson et al., 2003), we can
conclude that such C-terminus sequence is suffi-
cient for the binding of 1188-2 antibody.
Thus, we can show the following reactivity of
anti-prelamin A antibodies in human fibroblasts.
Antibody 1188-1  binds full-length prelamin A both
in its non-farnesylated and in its farnesylated form
(preLA-CSIM and preLA-farnesyl-CSIM).The far-
nesylated form of full-length prelamin A appears to
be labelled by the antibody with lower efficiency.
Antibody 1188-2 efficiently binds farnesylated
prelamin A devoid of the SIM C-terminal sequence,
following the first endoprotease cleavage, while it
does not recognise full-length prelamin A.
Further studies are needed to discriminate
whether or not antibody 1188-2 binding is affected
by prelamin A carboxymethylation.
Inhibition of ZMPSTE24 causes accumulation of
full-length farnesylated prelamin A
Data previously reported show that AFCMe and
HIV protease inhibitors used in this study impair
ZMPSTE24 activity  and cause accumulation of
farnesylated prelamin A (Kilic et al., 1997; Caron
et al., 2007; Coffinier et al., 2007; Coffinier et al.,
2008; Mattioli et al., 2008). In our experimental
models, carboxymethylated farnesylated  prelamin
A is detectable  at very low levels  after treatment
with endoprotease inhibitors. On the other hand, a
significant amount of full-length prelamin A is
accumulated, as indicated by the strong reactivity
of antibody 1188-1 in AFCMe- or HIV protease
inhibitor-treated cells.Therefore,our results strong-
ly suggest that blocking ZMPSTE24 activity in
human cells, mostly impairs the first cleavage step
of prelamin A (step 2 in Figure 1A) and only a
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Figure 4. Prelamin A Western blot analysis in control and HGPS skin fibroblasts. Western blot analysis of human fibroblast lysates per-
formed with antibody 1188-1, 1188-2 or anti-lamin A/C antibody is shown. (A) Analysis of cells forced to accumulate non-farnesylated
prelamin A. Cellular lysates have been obtained from control untreated fibroblasts (control), or from fibroblasts treated with FTI-277 or
mevinolin to accumulate non-farnesylated prelamin A. (B) Analysis of cells accumulating farnesylated prelamin A. Cells were treated with
the HIV protease inhibitors atazanavir, amprenavir, indinavir, nelfinavir, ritonavir+lopinavir and ritonavir+atazanavir (left panels) to accumu-
late farnesylated prelamin A. Analysis of lysates from AFCMe -treated control fibroblasts and untreated HGPS fibroblasts, known to accu-
mulate farnesylated prelamin A, is shown in the right panels. Atazanavir and amprenavir did not affect prelamin A processing and are used
as negative controls. Actin is labelled as a loading control. Asterisks indicate the shift of the prelamin A band detected by anti-lamin A/C
antibody.minor amount of precursor protein is allowed to
undergo further processing through RCE1 cleav-
age. However, this finding needs further deepening
since activation of the endoprotease RCE1,which is
suggested to carry-out the first cleavage step of
prelamin A processing in the absence of ZMP-
STE24 activity, could depend on several factors.
For instance, it could be triggered by a threshold
level of preLA-farnesyl-CSIM or by other unknown
stimuli involving cell signalling events. In this con-
text, however, it is noteworthy that HIV-protease
inhibitors, though administered to human fibrob-
lasts in long-term treatments, failed to induce high
levels of carboxymethylated farnesylated prelamin
A.We suggest that a relevant amount of preLA-far-
nesyl-C-CH3 is only accumulated if  prelamin A
mutations affect the availability of the second
ZMPSTE24 cleavage site, as it occurs in HGPS
cells (Eriksson et al., 2003) and possibly in other
LMNA-linked laminopathies.
Prelamin A processing in laminopathies
The antibodies we have obtained are a useful tool
for the study of prelamin A in progeroid
laminopathies,metabolic laminopathies and lipody-
strophies (Navarro et al., 2004; Capanni  et al.,
2005; Filesi et al., 2005; Glynn and Glover, 2005;
Caron  et al., 2007). Data so far reported show
involvement of farnesylated prelamin A in these dis-
orders (Maraldi and Lattanzi,2007).It is notewor-
thy,however,that the presence of carboxymethylat-
ed farnesylated prelamin A could not be investigat-
ed so far in laminopathic cells, except than in
HGPS as progerin, since antibodies specifically
directed to  preLA-farnesyl-C-CH3 were not avail-
able. Therefore, testing of laminopathic cells with
antibody 1188-2 could give important insights.
Moreover, the use of 1188-1 or 1188-2 antibody
in the analysis of prelamin A processing in patholog-
ical and experimental models may give new insights
into the function of the lamin A precursor relative to
the post-translational modification harboured by the
protein (Barton and Worman,1999;Capanni et al.,
2005; Taylor  et al., 2005; Crisp  et al., 2006;
Lattanzi et al.,2007;Mattioli et al.,2008).In fact,
while prelamin A toxicity has been so far attributed
to the carboxymethyl-farnesyl residue of prelamin A
(Glynn and Glover, 2005), the effect of full-length
farnesylated prelamin A accumulation is still
unknown. However, we recently published that
AFCMe treatment leads to formation of highly dys-
morphic nuclei in human fibroblasts and to severe
heterochromatin loss and LAP2α mislocalization
(Mattioli et al., 2008). Based on the data obtained
in the present study, those pathogenetic effects can
be ascribed to farnesylated prelamin A in its full-
length form.
Another unsolved question in the study of
prelamin A in laminopathies concerns the possibili-
ty that inhibition of one processing step may acti-
vate feedback mechanisms leading to accumulation
of other prelamin A forms. For instance, we cannot
exclude that blockade of ZMPSTE24 activity may
also affect protein farnesylation due to a feedback
mechanism. In the context of laminopathy studies,
this issue appears particularly relevant. In fact,
although the farnesyl residue has been shown to
confer toxicity to prelamin A and to cause nuclear
dysmorphism (Glynn and Glover, 2005; Caron et
al., 2007), we cannot rule out that more than one
prelamin A form might be accumulated in lamino-
pathic cells and that the rate between different
prelamin A forms might affect the severity of the
disease.
Finally, detection of prelamin A forms in lamino-
pathic cells may help setting therapeutic strategies,
mostly those based on the use of inhibitors of
prelamin A farnesylation (Columbaro et al., 2005;
Yang et al., 2005).
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